Citations

Clear

3942 citation(s) found for "To, Van".

Clinical Phenotypes of Alzheimer’s Disease: Atrophy Patterns and their Pathological Correlates
Reijner, Niels , Bouwman, Maud M.A. , Guizard, Nicolas , Jubault, Thomas, Gordón, Elizabeth , Frigerio, Irene , Boon, Baayla D.C. , Hoozemans, Jeroen J.M. , Rozemüller, Annemieke J.M. , Bouwman, Femke H. , Barkhof, Frederik , Berg, Wilma D. J. van de , Jonkman, Laura E.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.087358 Get It

AbstractBackgroundRecent studies highlight distinct patterns of cortical atrophy between amnestic (typical) and non‐amnestic (atypical, with subtypes: behavioural, dysexecutive, logopenic and visuospatial) clinical phenotypes of Alzheimer’s disease (AD). The current study aimed to assess regional MRI patterns of cortical atrophy across AD phenotypes, and their association with amyloid‐beta (Aβ), phosphorylated tau (pTau), axonal degeneration (NfL) and microvascular deterioration (COLIV).MethodPostmortem In‐situ 3DT1 3T‐MRI data was collected for 33 AD (17 typical, 16 atypical) and 16 control brain donors. Images were segmented and AAL3 atlas regional volumes were obtained using QyScore®. At subsequent autopsy, eight brain regions were selected, immunostained for Aβ (4G8), pTau (AT8), Neurofilament‐light (NFL), and Collagen‐IV (COLIV), and quantified using qupath. Group comparisons and volume‐pathology associations were analyzed using linear models and partial correlations with covariates age, sex, postmortem delay, and intracranial volume.ResultsCompared to controls, AD phenotype groups showed overall lower cortical volume, while only minor volume differences were observed between AD phenotype groups, observed primarily in limbic regions (Fig. 1). Across pathological markers, AD phenotype groups showed consistently higher immunoreactivity than controls, while atypical AD showed consistently higher immunoreactivity than typical AD (Fig. 2). Moreover, different patterns of pathology could be observed between atypical subtypes (e.g. distinctly higher pTau load in the occipital gyrus of the visuospatial subtype). In typical AD, global volume loss was associated with lower Aβ and higher pTau, NFL and COLIV immunoreactivity, while in atypical AD, global volume loss was primarily associated with higher NFL immunoreactivity (Fig. 3a). Regionally, AD phenotype differences in atrophy‐pathology association were most pronounced in the (para) hippocampal regions. This distinction was mainly characterized by negative associations for NFL and COLIV, which was only observed in typical AD (Fig. 3b‐c).ConclusionAtrophy patterns between AD phenotypes showed only minor differences, potentially attributable to the on average later disease stage of the study cohort. The higher immunoreactivity for pathological markers found in atypical AD might suggest a more severe disease burden. (Para) hippocampal volume decline was associated with axonal and microvascular deterioration in typical AD, but not in the higher pathologically burdened atypical AD group, suggesting a differential susceptibility between AD phenotypes.
Modeling sex differences in Alzheimer’s Disease using isogenic hiPSC lines with different sex chromosome complements and APOE alleles
Filippova, G. N. , Casad, Michelle , Groneck, Camille, Hui, Katherine, Mishra, Swati , Bammler, Theo K. , Dyke, Daniel L. Van , Skakkebæk, Anne , Gravholt, Claus Højbjerg , Mathieu, Julie , Berletch, Joel B. , Jayadev, Suman , Gravholt, Claus H , Hui, Katherine, MacDonald, James W. , Deng, Xinxian , Distèche, Christine M. , Young, Jessica E.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.093548 Get It

AbstractBackgroundLate Onset Alzheimer’s Disease (LOAD) is the most common neurodegenerative disorder. Carriers of an ɛ4 allele of the apolipoprotein E gene (APOE) have significantly increased risk of developing LOAD. LOAD is also strongly sex biased. Besides the well‐established role of sex hormones, the impact of genetic sex combined with APOE genotypes has not been studied. Sex chromosome dosage (SCD) is the main genetic difference between females (XX) and males (XY). Despite dosage compensation by X chromosome inactivation (XCI), some X‐linked genes remain expressed from the inactive X (Xi) and are female biased in expression. Many of these genes are related to neurological and immune functions and could contribute to neuroinflammation in AD.MethodTo understand the genetic interactions between autosomal risk (APOE) and sex‐bias in AD, we are generating isogenic sets of hiPSCs with various sex chromosome complements and APOE genotypes. We have derived XXY/XY, XY/X, and XX/X isogenic pairs by reprogramming cells from naturally mosaic individuals or by selective removal of the Xi in vitro. These lines uniquely position us to differentiate the effects of X chromosome dosage and/or presence of a Y chromosome, while minimizing genetic variability and environmental or hormonal confounders. Currently, we are also constructing APOE ɛ3 and ɛ4 alleles in our paired hiPSC lines with differing sex chromosome content using gene editing.ResultStarting from an XXY/XY isogenic pair, we have generated an hiPSC series with six different genotypes of APOE ɛ3/ɛ3, ɛ3/ɛ4 or ɛ4/ɛ4 alleles with either the XXY or XY genotype. Preliminary results in differentiated neural precursor cells show differential expression of sex‐linked genes in relation to SCD. We also observed genome‐wide changes in gene expression and DNA methylation. Subsets of autosomal sex‐biased genes were differentially affected either by X chromosome dosage, presence of a Y, or both.ConclusionThe new hiPSC lines are being differentiated to AD‐relevant cell types, including neurons, microglia, and cortical organoids, for transcriptomic and functional analyses to elucidate how APOE alleles and genetic sex interact to modulate risk in LOAD pathology.
ECONOMIC VALUE OF UNPAID FAMILY CAREGIVER TIME FOLLOWING HOSPITAL DISCHARGE AND AT END-OF-LIFE
Zhang, Wenhan , Shibeika, Sahar , Huang, Ro W. , Vanderboom, Catherine E., Holland, Diane E. , Houtven, Courtney H. Van , Kaufman, Brystana G. , Wenhan, Zhang, Griffin, Joan M.

Mayo Clinic

Innovation in Aging | January 1, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: 144-145

10.1093/geroni/igae098.0465 Get It

Abstract Estimates of patient care costs often overlook the economic value of unpaid caregiving. This study aims to quantify the economic value of unpaid caregiving by rural FCGs. Using data from a multi-site randomized controlled trial evaluating Transitional Palliative Care (TPC) intervention for FCGs, this study quantifies the economic value of family caregiving in the six months following seriously ill care recipients’ hospital discharge using three valuation methods. Caregiving hours were self-reported by FCGs. The proxy cost approach assigned value to FCG hours using the national median home health aide wage. The unadjusted opportunity cost approach assigned value using the national median wage, by sex and education level. The adjusted opportunity cost approach assigned value by work force participation, using opportunity cost if employed and proxy cost otherwise. Of 282 FCGs, 94% were non-Hispanic White, 71% had a college degree, 56% were spouses, and 51% were in the workforce. FCG cost did not differ by treatment arm. FCGs of decedents compared to survivors reported significantly more hours per person-month (392 vs. 272, p< 0.001), resulting in higher median opportunity cost ($12,653 vs. $8,843, p< 0.001), proxy cost ($5,689 vs. $3,955, p< 0.001), and adjusted opportunity cost ($9,490 vs. $6,443, p< 0.001) per person-month. Proxy cost may undervalue FCG time, while opportunity cost may perpetuate labor market inequities. Policymakers must weigh trade-offs of different valuation methods. The high intensity of unpaid post-acute care, especially end-of-life, should be considered when designing policies and interventions to support unpaid FCG due to the economic impact on FCGs and employers.
A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery
Riviere-Cazaux, Cécile , Warrington, Arthur E. , Hoplin, Matthew D. , Andersen, Katherine M., Malik, Noor , Palmer, Elizabeth, Dasari, Surendra , Munoz-Casabella, Amanda , Ikram, Samar, Jusué-Torres, Ignacio , Meyer, Fredric B. , Kizilbash, Sani H. , Campian, Jian , Palmer, Elizabeth A, Carlstrom, Lucas P. , Sarkaria, Jann N , Van Gompel, Jamie J , Kizilbash, Sani H , Jusue-Torres, Ignacio , Malik, Noor , Michor, Franziska , Ghadimi, Keyvan , Himes, Benjamin , Sarkaria, Jann N. , Gompel, Jamie J. Van , Sener, Uğur , Parney, Ian F. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | December 27, 2024 | Volume: 27 | Issue: 4 | Pages: 948-962

10.1093/neuonc/noae277 | PMID 39786485 Get It

Abstract Background While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown. Methods Aptamer-based proteomics was performed on 147 CSF samples from 74 patients; 71 of whom had grade 2–4 astrocytomas or grade 2–3 oligodendrogliomas. This included pre- versus post-resection intracranial CSF samples obtained at early (1–16 days; n = 20 patients) or delayed (86–153 days; n = 11 patients) time points for patients with glioma. Paired lumbar versus intracranial glioma CSF samples were also obtained (n = 14 patients). Results Significant differences were identified in the CSF proteome between lumbar, subarachnoid, and ventricular CSF in patients with gliomas. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome, with distinct sets of proteins present at different time points since resection. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, such as bevacizumab and immunotherapies. Conclusions The intracranial glioma CSF proteome serves as a rich and dynamic reservoir of potential biomarkers that can be used to evaluate the effects of resection and other therapies over time. All data within this study, including detailed individual clinical annotations, are shared as a resource for the neuro-oncology community to collectively address these unanswered questions and further understand glioma biology through CSF proteomics.
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
Bekaii‐Saab, Tanios , Cercek, Andrea , Heinemann, Volker , Raghav, Kanwal Pratap Singh, Yoshino, Takayuki, Ramos, Jorge , Guan, Xuesong, André, Thierry , Bekaii-Saab, Tanios S , Strickler, John H. , Nakamura, Yoshiaki, Siena, Salvatore , Tabernero, Josep , Cutsem, Eric Van , Yoshino, Takayuki , André, Thierry

Mayo Clinic

Future Oncology | December 26, 2024 | Volume: 21 | Issue: 3 | Pages: 303-311

10.1080/14796694.2024.2441101 | PMID 39723627 Get It

Psychotropic medication usage in sporadic versus genetic behavioral‐variant frontotemporal dementia
Vargas‐González, Juan‐Camilo , Dimal, Nico , Cortez, Kasey, Heuer, Hilary W. , Forsberg, Leah K. , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R., Grant, Ian , Kantarci, Kejal , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Roberson, Erik D. , Rogalskı, Emily , Boxer, Adam L. , Rosen, Howie, Damme, Philip Van , Boeve, Brad F, Roberson, Erik , Kantarci, Kejal , Van Damme, Philip , Pascual, Belen , Domoto-Reilly, Kimiko , Barmada, Sami , Appleby, Brian S. , Bozoki, Andrea C , Clark, David , Cobigo, Yann , Dickerson, Bradford Clark , Galasko, Douglas , Graff‐Radford, Neill R. , Irwin, David J. , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Boeve, Bradley F. , Tartaglia, Maria Carmela

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14448 | PMID 39713899 Get It

Abstract INTRODUCTION Psychotropic medication (PM) use in behavioral‐variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD. METHODS We analyzed data from sporadic and genetic bvFTD participants with PM prescriptions in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects study. We estimated ordinal odds ratio (OOR) of having more PM comparing sporadic and genetic bvFTD. Finally, we explored the neuropsychiatric symptom (NPS) combinations using classification and regression trees (CART). RESULTS We included 263 with sporadic and 193 with genetic bvFTD. The OOR for sporadic bvFTD to be on PM was 1.75 (95% confidence interval: 1.21 to 2.53) for the fully adjusted model. CART revealed the most common NPS combination was apathy + personality changes in 18% of participants. DISCUSSION Participants with sporadic bvFTD were twice as likely to be on PM compared to genetic bvFTD. The reason for increased PM usage in sporadic bvFTD participants should be further investigated. Highlights We report on patients with behavioral variant frontotemporal dementia (bvFTD). We evaluated the psychotropic medication (PM) prescription at baseline in the cohort. Patients with sporadic bvFTD had more prescriptions for PM than genetic patients. The frequency of symptoms combination was different in sporadic and genetic bvFTD.
Prognostic Implications of Right Ventricular Dysfunction in Severe Degenerative Mitral Regurgitation
Bohbot, Yohann , Essayagh, Benjamin , Benfari, Giovanni , Bax, Jeroen J. , Tourneau, Thierry Le , Topilsky, Yan , Antoine, Clémence , Ruşinaru, Dan, Grigioni, Francesco , Roussel, Jean‐Christian , Thapa, Prabin , Tribouilloy, Christophe , Le Tourneau, Thierry , Marsan, Nina Ajmone , van Wijngaarden, Aniek , Hochstadt, Aviram , Roussel, Jean-Christian , Diouf, Momar , Thapa, Prabin , Michelena, Hector I , Enriquez-Sarano, Maurice , Tribouilloy, Christophe , Bax, Jeroen J , Benfari, Giovanni , Bohbot, Yohann , Essayagh, Benjamin , Grigioni, Francesco , Marsan, Nina Ajmone , Wijngaarden, Aniek L. van , Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Mayo Clinic

Journal of the American Heart Association | December 18, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1161/jaha.124.036206 | PMID 39692024 Get It

Background The prevalence and impact of right ventricular dysfunction (RVD) in degenerative mitral regurgitation (DMR) is unknown. We aimed to determine whether RVD assessed by echocardiography in routine clinical practice is independently associated with mortality in patients with DMR. Methods and Results We used data from the MIDA‐Q (Mitral Regurgitation International DAtabase‐Quantitative) registry, which included patients with isolated DMR due to mitral valve prolapse from January 2003 to January 2020 from 5 tertiary centers across North America, Europe, and the Middle East. A cohort of 2917 (mean age: 66 years, 70.8% male patients, follow‐up: 5.2 [3.3–8.3] years) consecutive patients with severe DMR was included and long‐term mortality was analyzed. RVD, identified in 426 (14.6%) patients, was associated with reduced 8‐year survival (55%±3% versus 77%±1%; P <0.001), overall and in all subgroups of patients, even after comprehensive adjustment including left ventricular dilatation and dysfunction, DMR severity, pulmonary pressures, and surgery (adjusted hazard ratio, 1.44 [95% CI, 1.17–1.77]; P <0.001). This excess mortality was observed under medical management (adjusted hazard ratio, 1.57 [95% CI, 1.20–2.05]; P =0.001) and after surgical correction of mitral regurgitation (adjusted hazard ratio, 1.45 [95% CI, 1.02–2.05]; P =0.039). Patients with RVD undergoing surgery within 3 months of diagnosis experienced a better 8‐year survival (73%±4% versus 43%±4%; P <0.001), even after adjustment (adjusted hazard ratio, 0.44 [95% CI, 0.29–0.67]; P <0.001) despite an increase of 1‐month postoperative mortality (7.1% versus 0.5% for patients without RVD; P <0.001). Conclusions RVD is observed in 14.6% of severe DMR and exhibits a powerful and independent association with excess mortality partially attenuated by mitral surgery. Therefore, assessment of right ventricular systolic function should be included in routine DMR evaluation and in the clinical decision‐making process.
Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference
Kloske, Courtney M. , Batista, André F., Carrillo, María C. , Chakrabarty, Paramita , Chen, Xiaoying , Craft, Suzanne , Mesquita, Sandro Dá , Devanand, Davangere P. , Durán‐Laforet, Violeta , Fitzgerald‐Bocarsly, Patricia , Hong, Soyon , Jackvony, Stephanie , Lai, Laijun , Liddelow, Shane A. , Martín‐Peña, Alfonso , Orr, Anna G. , Quintana, Francisco José López , Ramey, G. , Sexton, Claire E. , Torrellas, Jose, Tsai, Andy P. , Wharton, Whitney , Da Mesquita, Sandro , Mahinrad, Simin , Barnum, Christopher J. , Bradshaw, Elizabeth M. , Butts, Brittany , Dabin, Luke Child , Elyaman, Wassim , Evans, Elizabeth E. , Foley, Kate E. , Harms, Ashley S. , Heneka, Michael T. , Huang, Yu‐Wen Alvin , Le Guen, Yann , Lemere, Cynthia Ann , Quintana, Francisco J., Rexach, Jessica E. , Rizzo, Stacey J. Sukoff , Tang, Alice , Olst, Lynn van , Walker, Keenan A. , Tansey, Malú G. , Wilcock, Donna M.

Mayo Clinic

Alzheimer's & Dementia | December 18, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14291 | PMID 39692624 Get It

Abstract The immune system is a key player in the onset and progression of neurodegenerative disorders. While brain resident immune cell‐mediated neuroinflammation and peripheral immune cell (eg, T cell) infiltration into the brain have been shown to significantly contribute to Alzheimer's disease (AD) pathology, the nature and extent of immune responses in the brain in the context of AD and related dementias (ADRD) remain unclear. Furthermore, the roles of the peripheral immune system in driving ADRD pathology remain incompletely elucidated. In March of 2023, the Alzheimer's Association convened the Alzheimer's Association International Conference (AAIC), Advancements: Immunity, to discuss the roles of the immune system in ADRD. A wide range of topics were discussed, such as animal models that replicate human pathology, immune‐related biomarkers and clinical trials, and lessons from other fields describing immune responses in neurodegeneration. This manuscript presents highlights from the conference and outlines avenues for future research on the roles of immunity in neurodegenerative disorders. Highlights The immune system plays a central role in the pathogenesis of Alzheimer's disease. The immune system exerts numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The 2023 AAIC, Advancements: Immunity, encouraged discussions and collaborations on understanding the role of the immune system.
Seizure Detection and Lateralization Using Thalamic Deep Brain Stimulator Recordings
Ortiz‐Guerrero, Gloria , Park, Sihyeong , Starnes, Keith , Brinkmann, Benjamin H. , Gregg, Nicholas M. , Brinkmann, Benjamin H , Gregg, Nicholas M , Ortiz-Guerrero, Gloria , Starnes, Donnie Keith , Lundstrom, Brian N. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

Journal of Clinical Neurophysiology | December 18, 2024 | Volume: 42 | Issue: 3 | Pages: 279-283

10.1097/wnp.0000000000001137 | PMID 39690452 Get It

Summary: The lack of reliable seizure detection remains a significant challenge for epilepsy care. A clinical deep brain stimulation (DBS) system provides constrained ambulatory brain recordings; however, limited data exist on the use of DBS recordings for seizure detection and lateralization. We present the case of an 18-year-old patient with drug-resistant focal epilepsy, who had seizure detection and lateralization by DBS recordings. Prior stereotactic-EEG, including a thalamus lead, identified independent left orbitofrontal and mesial temporal onset seizures. Notably, low-frequency thalamic ictal power was significantly elevated relative to baseline awake and sleep states. The patient was subsequently implanted with an anterior nucleus of the thalamus DBS system. Postimplantation, low-frequency power-in-band (5.3–10.3 Hz) recordings were initiated. Nursing staff identified four typical clinical seizures during the inpatient DBS recording period. Thalamic DBS trends contained relative peaks that were coincident with each nurse-reported seizure. Peri-ictal power was uniformly maximal ipsilateral to the seizure network. This case demonstrates the feasibility of seizure detection and lateralization by a thalamic DBS system for some individuals, and suggests DBS sensing parameter selection may be guided by thalamic stereotactic EEG. Further research is necessary to assess the generalizability of DBS seizure detection across individuals and diverse seizure networks.
Stiffness analysis of meningiomas using neural network-based inversion on MR Elastography
Murphy, Matthew C. , Camerucci, Emanuele , Plitt, Aaron , Shan, Xiang , Zheng, Keni , Sui, Yi, Manduca, Armando , Gompel, Jamie J. Van , Ehman, Richard L. , Huston, John , Yin, Ziying

Mayo Clinic

2024 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) | December 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/embc53108.2024.10781605 | PMID 40039666 Get It